Conjunctival stromal tumor in an 18-month-old girl: A case report Authors: Harrison Zhang Dai, Rachel Kim Sobel, Caitlin Hughes Published: 2026 ABSTRACT PurposeTo report an unusual case of conjunctival stromal tumor (COST) located in the punctum of the eyelid in an 18-month-girl.ObservationThe patient is an 18-month female, with no significant medical history or ocular trauma, who presented with a slowly growing mass on the punctum of her right-upper eyelid. Ophthalmic exam showed that the lesion was not attached to the globe of the eye. The lesion was completely surgically excised. Histopathological analysis showed a well-circumscribed polypoid nodule comprised of bland spindled cells with pseudonuclear inclusions and giant cells with floret-like nuclear configurations. The immunohistochemical staining pattern was consistent with COST.ConclusionCOST is an emerging entity first described in 2012 and rarely reported in children. Herein, we report the third diagnosis of COST in a child, the youngest age reported to date. As such, it should be considered in the differential diagnosis of a conjunctival lesion regardless of age. In the differential diagnosis, it is important to distinguish COST from conjunctival myxoma given the syndromic associations of the latter. Introduction Conjunctival stromal tumor (COST) was first described in a case series in 2012 as a benign mesenchymal proliferation containing spindle cells, pseudonuclear inclusions, and multi-nucleated giant cells with floret configurations.1 COST currently remains a relatively rare diagnosis with less than 60 cases reported in the literature.2 Herein, we report a case of COST in an unusual location involving the right-upper punctum in an 18-month-old child. Case report The patient is an 18-month-old female with a right-upper eyelid punctal mass (Fig. 1). Her parents noted a slowly growing fleshy-appearing mass on the right-upper lid when she was about 14 months old. There is no other pertinent medical history, family history of syndromic conditions, or prior ocular trauma. The mass was not to be painful, though the patient occasionally rubbed the lesion. The ophthalmic exam showed that the lesion was not attached to the globe of the eye and there was no amblyopia or visual deficits. The remainder of the patient's ocular exam was normal. At the time, surgical intervention was recommended.Fig. 1Right upper punctal mass. The lesion is not attached or adherent to the globe of the eye. Right upper punctal mass. The lesion is not attached or adherent to the globe of the eye. Intraoperatively, the mass appeared to emanate from the region of the punctum. The proximal portion of the punctum was removed with the lesion, leaving the distal canaliculus with respect to the lesion and the lacrimal system intact. Grossly, the excised lesion measured 0.7 x 0.6 × 0.4 cm and was ivory in color with a gelatinous homogenous consistency. Histopathological analysis showed mostly stratified squamous epithelium with minimal conjunctival epithelium overlying a paucicellular nodule (Fig. 2A). The nodule was comprised of spindled cells with some pseudonuclear inclusions, multinucleated floret-like giant cells, and sparse mixed inflammatory cells in a background of loose, wiry stroma (Fig. 2B–C). The spindled cells were BCL-2 and CD34-positive (Fig. 2D) with retained RB1 and INI-1 staining by immunohistochemical (IHC) staining. The multinucleated floret-like giant cells seen were positive for histiocytic markers CD68 and Factor XIIIa (Fig. 2E). Both the spindled and multinucleated cells were negative for desmin, myogenin, MyoD1, SOX10, and STAT-6. ERG highlighted background vascular endothelial cells. Additional special stains for Alcian blue (Fig. 2F), colloidal iron, MUC4, and ALK were negative. Taken together, the morphological and immunophenotypic characteristics were consistent with a diagnosis of a conjunctival stromal tumor.Fig. 2Representative hematoxylin and eosin (H&E) and immunohistochemical stains of the patient's punctal lesion. A) A well-circumscribed, polypoid punctal lesion (H&E, 20X). B) Stratified, keratinized squamous (arrow) and minimal conjunctival epithelium overlying a paucicellular stroma (H&E, 100X). C) Lesion comprising of spindled cells (arrow), focal pseudonuclear inclusions, and multinucleated floret-like giant cells (arrowhead) (H&E, 200X). D) Lesional cells demonstrating CD34 immunoreactivity (arrow) with background unremarkable blood vessels also staining with CD34 (arrowhead) (100X). E) Lesional dendritic cells are positive for Factor XIIIa (arrow) (100X). F) Alcian blue special staining shows no background mucin (100X). Representative hematoxylin and eosin (H&E) and immunohistochemical stains of the patient's punctal lesion. A) A well-circumscribed, polypoid punctal lesion (H&E, 20X). B) Stratified, keratinized squamous (arrow) and minimal conjunctival epithelium overlying a paucicellular stroma (H&E, 100X). C) Lesion comprising of spindled cells (arrow), focal pseudonuclear inclusions, and multinucleated floret-like giant cells (arrowhead) (H&E, 200X). D) Lesional cells demonstrating CD34 immunoreactivity (arrow) with background unremarkable blood vessels also staining with CD34 (arrowhead) (100X). E) Lesional dendritic cells are positive for Factor XIIIa (arrow) (100X). F) Alcian blue special staining shows no background mucin (100X). Post-operatively, the patient recovered well with no complications. The patient is being followed up periodically with no evidence of lesion recurrence. Discussion Conjunctival stromal tumor (COST) is a rare neoplasm estimated to represent <0.001 to <0.2% of all conjunctival lesions.2,3 The pathogenesis of COST remains unknown, but it is speculated to originate from either underlying reactive or inflammatory processes.4 It was first described in 2012 and is currently classified by the World Health Organization (WHO) as a fibrous/fibroblastic tumor that exists on a spectrum with ocular surface fibromas.5 This lesion has been observed to occur most frequently in middle-aged adults but has also been reported to affect the pediatric population in two cases.6,7 Clinically, COST has been observed as a heterogenous lesion found most frequently in the bulbar conjunctiva and may appear as a translucent to reddish-pink mass.4 In this case, the lesion appeared to be clinically involving the punctum. Histologically, the lesion arose from a minute portion of conjunctival epithelium. COSTs are generally managed by surgical intervention whereby complete excision is curative. Periodic follow-up to assess for recurrence is recommended.2,4,8 Histologically, COST is characterized as a well-circumscribed neoplasm that consists of spindle cells, pseudonuclear inclusion bodies, and multinucleated giant cells. The multinucleated giant cells may exhibit floret-like nuclear configurations. COST has a stromal background that can range from myxoid to collagenous-appearing.1, 2, 3,9 In a series of four cases by Herwig et al., all COSTs were positive for CD34 and vimentin, focally positive for CD68, and negative for S100, SOX10, and SMA.1 Additional COST case reports have described positive staining for BCL-2, Alcian Blue, and retained RB1.1, 2, 3,6,9 Although COST is a benign neoplasm, it is important to distinguish it from conjunctival myxoid stromal tumor as the latter entity has an association with potentially life-threatening cardiac myxomas and syndromic conditions such as Carney complex and Zollinger-Ellison syndrome.10,11 Differentiating COST and conjunctival myxoma is challenging as both entities share overlapping morphologic and immunohistochemical features.6,9 As compared with conjunctival myxomas, COSTs are typically more cellular and contain more multinucleated giant cells and spindled morphology.9 Additionally, COSTs have been reported to more commonly contain an inflammatory infiltrate with CD68-positive histiocytes and Factor XIIIa-positive dendritic cells compared with conjunctival myxomas.9 Conclusion COST remains a poorly understood entity due to its relatively recent description and the sparsity of current literature pertaining to the diagnosis. This case report adds to the limited literature on COST by describing an unusual location, centered primarily in the punctum, affecting the youngest patient yet reported at 18 months of age. As such, despite its rarity and propensity to affect adults, it should be considered in the differential diagnosis of a conjunctival lesion regardless of age. It is important to distinguish COST from conjunctival myxoma given the syndromic associations of the latter. CRediT authorship contribution statement Harrison Zhang Dai: Writing – review & editing, Writing – original draft, Resources. Rachel Kim Sobel: Writing – review & editing, Data curation, Conceptualization. Caitlin Hughes: Writing – review & editing, Supervision, Conceptualization. Consent Written consent was obtained from the patient's parents and is submitted in conjunction with this case report. Funding No funding was received for this report. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.